Helus Pharma Adds Veteran HR Executive Jill Conwell as Chief People Officer — Cybin Inc.

Event summary

Jill Conwell appointed Chief People Officer at Helus Pharma, effective March 12, 2026.
Conwell brings over 20 years of HR and organizational strategy experience in the pharmaceutical industry.
Helus Pharma is advancing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
Conwell previously held senior roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals.

The big picture

Helus Pharma's appointment of Jill Conwell as Chief People Officer underscores its focus on organizational maturity as it advances its novel serotonergic agonists through clinical trials. The move comes at a critical juncture for the company, with HLP003 in Phase 3 development for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder. Conwell's extensive experience in building and scaling teams within the pharmaceutical industry positions her to support Helus Pharma's next phase of growth, particularly as it navigates the complexities of commercializing innovative mental health treatments.

What we're watching

Organizational Scaling: How Conwell's expertise will impact Helus Pharma's ability to scale its organization during rapid growth and clinical pipeline advancement.
Talent Attraction: Whether Conwell can help attract top talent to support Helus Pharma's ambitious scientific and strategic goals.
Cultural Alignment: The pace at which Conwell can align Helus Pharma's teams and processes to maintain a strong, collaborative, and mission-driven culture.